Corporate Events

Daito Pharmaceutical Co.,Ltd. (TSE:4577), Development Bank of Japan Inc. and Meiji Seika Pharma Co., Ltd signed a Memorandum of Understanding to acquire KYORIN Rimedio Co., Ltd from KYORIN Pharmaceutical Co., Ltd. (TSE:4569) on April 24, 2026. Daito Pharmaceutical Co.,Ltd. Development Bank of Japan Inc. and Meiji Seika Pharma Co., Ltd entered into a Share Transfer Agreement to acquire KYORIN Rimedio Co., Ltd from KYORIN Pharmaceutical Co., Ltd. on September 30, 2026. Prior to the closing, the KYORIN Rimedio Co., Ltd will undergo a pre-closing reorganization through two absorption-type company splits: it will absorb the Takaoka and Inami plants from KYORIN Pharmaceutical Group Facilities Co., Ltd., and simultaneously transfer its authorized generic (AG) business to the same entity, KYORIN Pharmaceutical Group Facilities Co., Ltd. The expected completion of the transaction is April 1, 2027.

KYORIN Pharmaceutical Co., Ltd., Board Meeting, Sep 30, 2026. Agenda: To consider to have the Target Company succeed to, from KYORIN Pharmaceutical Group Facilities, the assets, liabilities,and other rights and obligations constituting the Target Plants held by KYORIN Pharmaceutical Group Facilities through an absorption-type company split, where KYORIN Pharmaceutical Group Facilities is the splitting company and the Target Company is the succeeding company; and to consider the other matters.

KYORIN Pharmaceutical Co., Ltd. announced that it will commence promotion activities for Alesion eyelid cream 0.5% (generic name: epinastine hydrochloride, hereinafter Alesion Cream), a long-acting treatment for allergic conjunctivitis, effective August 17, 2026. This initiative is based on the joint marketing agreement in Japan for Alesion Cream, which was executed on July 13, 2026 with Santen Pharmaceutical Co., Ltd. Under the agreement, Santen will continue to be responsible for manufacturing, product distribution, and detailing for medical institutions specializing in the field of ophthalmology, with KYORIN handling detailing for medical institutions outside this field. The two partners—KYORIN, with expertise in allergic diseases and a strong sales and marketing platform in the respiratory and otolaryngology fields, and Santen, a company specialized in ophthalmology, expect this joint marketing to enable them to deliver Alesion Cream, a new treatment option for allergic conjunctivitis, to as many patients as possible, thereby contributing to improved patient quality of life (QOL). If any matters arise that require timely disclosure regarding the impact of this matter on the consolidated earnings forecast for the fiscal year ending March 31, 2027, KYORIN will promptly announce them. Allergic conjunctivitis is typically treated with anti-allergy eye drops (mediator release inhibitors and histamine H1 receptor antagonists) which require application to the eye twice or four times a day. Alesion Cream, which requires application only once daily to the periocular area (upper and lower eyelids), is the world’s first cream treatment for allergic conjunctivitis. It was developed by Santen in the hope that this new formulation will eliminate the burden for patients to take their required dose, thereby improving patient adherence. Alesion Cream’s active ingredient is epinastine hydrochloride, a histamine H1 receptor antagonist which suppresses the release of chemical mediators from mast cells, making it an effective treatment option for the condition.

KYORIN Pharmaceutical Co., Ltd., ¥ 10.0, Cash Dividend, Sep-29-2026

KYORIN Pharmaceutical Co., Ltd. announced that it has entered into joint marketing agreement in Japan for Alesion eyelid cream 0.5%, (generic name: epinastine hydrochloride, hereinafter Alesion Cream), a long-acting treatment for allergic conjunctivitis with Santen Pharmaceutical Co., Ltd. Alesion Cream is a treatment for allergic conjunctivitis developed by Santen with the aim of improving patient adherence and reducing treatment burden compared with conventional anti-allergic eye drops. As a cream formulation applied once daily to the periocular area (upper and lower eyelids), it has been marketed in Japan since May 22, 2024. Under the agreement, Santen will continue to be responsible for manufacturing, product distribution, and detailing for medical institutions specializing in the field of ophthalmology, with KYORIN handling detailing for medical institutions outside this field from around August 2026. The two partners—KYORIN, with expertise in allergic diseases and a strong sales and marketing platform in the respiratory and otolaryngology fields, and Santen, a company specialized in ophthalmology, expect the joint marketing agreement to enable them to deliver Alesion Cream, a new treatment option for allergic conjunctivitis, to as many patients as possible, thereby contributing to improved patient quality of life (QOL). If any matters arise that require timely disclosure regarding the impact of this matter on the consolidated earnings forecast for the fiscal year ending March 31, 2027, KYORIN will promptly announce them.

KYORIN Pharmaceutical Co., Ltd. provided cash dividend guidance for the second quarter-end and year-end of fiscal year ending March 31, 2027. For the second quarter-end of the fiscal year ending March 31, 2027, the company expects to pay a cash dividend of JPY 10.00 per share compared to JPY 20.00 per share paid a year ago. For the year ending March 31, 2027, the company expects to pay a year-end cash dividend of JPY 15.00 per share, compared to JPY 37.00 per share a year ago.

KYORIN Pharmaceutical Co., Ltd. announced that Mr. Michiro Onota will retire as Executive Director, Managing Corporate Officer CMO, in charge of Quality Assurance & Reliability HQs and SCM Chairman of KYORIN Pharmaceutical Group Facilities Co., Ltd. at the Ordinary General Meeting of Shareholders to be held on June 19, 2026, and is scheduled to be appointed as an Advisor thereafter. The company also announced that Mr. Noriyuki Shikanai will retire as Outside Director at the Ordinary General Meeting of Shareholders to be held on June 19, 2026.

KYORIN Pharmaceutical Co., Ltd. announced a year-end cash dividend of JPY 37.00 per share for the year ended March 31, 2026, compared to JPY 32.00 per share paid a year ago. The scheduled date to commence dividend payments is June 4, 2026.

KYORIN Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first half and full fiscal year ending March 31, 2027. For the first half, the company expects net sales of JPY 57,800 million, operating profit of JPY 300 million. For the full year, the company expects net sales of JPY 121,800 million, operating profit of JPY 2,000 million, profit attributable to owners of parent of JPY 1,500 million, and basic earnings per share of JPY 26.11.

KYORIN Pharmaceutical Co., Ltd., Board Meeting, May 20, 2026. Agenda: To consider Dividends from Retained Earnings.

KYORIN Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Jul 30, 2026

KYORIN Pharmaceutical Co., Ltd., Annual General Meeting, Jun 19, 2026.

KYORIN Pharmaceutical Co., Ltd., Board Meeting, Jun 19, 2026. Agenda: To consider announcement of Executive Personnel Changes.

KYORIN Pharmaceutical Co., Ltd., Board Meeting, May 12, 2026. Agenda: To consider the Notice regarding Partial Revision of Performance-Linked Stock Compensation Plan.

Daito Pharmaceutical Co., Ltd. entered into a Memorandum of Understanding with KYORIN Pharmaceutical Co., Ltd. to proceed with specific discussions regarding the succession of KYORIN's generic drug business by Pharmatech Co-creation Platform Inc. (tentative name), which Daito plans to newly establish with two other companies. The business to be succeeded includes KYORIN Rimedio Co., Ltd., a consolidated subsidiary of KYORIN engaged in the generic drug business, as well as the Takaoka Plant and Inami Plant of KYORIN Pharmaceutical Group Facilities Co., Ltd., a consolidated subsidiary responsible for production functions. Daito has been advancing the "Novel Consortium Initiative," designed to coordinate these efforts across multiple companies and address structural challenges facing the Japanese generic drug market. Daito has reached the Memorandum of Understanding to proceed with specific discussions for Pharmatech Co-creation Platform Inc. to be established primarily by the Company along with two other companies to succeed KYORIN’s Target Business, which possesses strong R&D capabilities, a robust quality assurance system, and highly efficient manufacturing capacity suitable for high-volume production. The contemplated transaction is expected to accelerate Daito’s DTP2027 strategy even more powerfully. Pharmatech Co-creation Platform Inc. is a platform that aims to upgrade the stable supply system centered on the upstream of the value chain (R&D, supply chain, manufacturing, and quality assurance), with the goals of "early resolution of supply instability" and "establishment of a resilient business foundation" in the generic drug industry. The joint venture will be formed through joint investment by Daito and two partner companies, with Daito expected to be the largest shareholder but not exceeding a majority stake. In line with government policy, Pharmatech Co-creation Platform Inc. also intends to pursue the integration of manufacturing and marketing authorization approvals and product brands. Daito will add value to Pharmatech Co-creation Platform Inc. through its industry-leading API R&D and supply capabilities in Japan, for which the domestic self-sufficiency rate continues to decline, as well as its high quality standards maintained through FDA certification for over 30 years. Together with its partners and the employees engaging with the Target Business, Daito aims to address critical social issues related to stable drug supply while enhancing its competitiveness of pharmaceutical manufacturing infrastructure. The date of resolution by the Board of Directors was April 24, 2026. The date of execution of Memorandum of Understanding was April 24, 2026. The date of execution of definitive agreement is scheduled for late September 2026. The effective date of succession is scheduled for April 1, 2027.

KYORIN Pharmaceutical Co., Ltd. announced that it has entered into an exclusive distribution and promotion agreement with Johnson & Johnson (the legal entity for the prescription pharmaceuticals business in Japan, operating as Janssen Pharmaceutical K.K., headquartered in Chiyoda-ku, Tokyo; President: Christopher Rieger) on March 25, 2026, for SIRTURO (Bedaquiline; the Product). The Product is currently marketed by Johnson & Johnson as a part of combination therapy in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). Johnson & Johnson is currently conducting Phase 2/3 clinical trials in patients with treatment-refractory Mycobacterium avium complex-lung disease (MAC-LD) to expand its approved indications. Under this agreement, KYORIN will commence sole promotional activities for the Product from June 2026. Upon obtaining approval for the additional indication of MAC-LD, KYORIN will receive product supply from Johnson & Johnson and exclusively distribute and promote the Product. The impact on business performance for the fiscal year ending March 31, 2026 is expected to be negligible. There are no capital, personnel, or business relationships between KYORIN and Johnson & Johnson, and neither party is considered a related party to the other.

KYORIN Pharmaceutical Co., Ltd. announced that effective April 1, 2026,Hiroki Usui has been appointed as Corporate Officer, Senior Director of Quality Assurance & Reliability HQs. He previously served as Associate Director of Quality Assurance, Quality Assurance & Reliability HQs. In addition, Kimiya Masada has been appointed as Director of Innovation Promoting and Corporate Officer. He formerly held the position of Director of Product Strategy.

KYORIN Pharmaceutical Co., Ltd., Board Meeting, Feb 26, 2026. Agenda: To consider and approve to introduce a Mandate-Based Corporate Officer System and approved the following executive appointments.

KYORIN Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval and received the approval certificate from Ministry of Health, Labour and Welfare (MHLW) for influenza virus nucleic acid kit, the "GeneSoC FluA/B Detection Kit" (hereinafter referred to as "the Product"), as an in vitro diagnostic (IVD). The Product is scheduled to be launched in the first half of fiscal year 2026. The Product is an IVD designed to assist in the diagnosis of influenza virus infections. When used in conjunction with "Genetic Analyzers GeneSoC mini 2" or " Genetic Analyzers GeneSoC mini", it can differentiate and detect Influenza A and B viruses in approximately 15 minutes. Compared to currently marketed "GeneSoC Influenza Virus A/B Detection Kit," the Product offers enhanced detection sensitivity and a shorter measurement time. It has been reported that nucleic acid amplification tests (NAAT) allow for diagnosis in the early stages of onset. The Product is expected to contribute to the rapid and accurate diagnosis of influenza virus infections. KYORIN remains committed to advancing the development and launch of IVD and research reagents dedicated to the GeneSoC in the areas of respiratory etc. Through these efforts, KYORIN aims to contribute to the diagnosis, prevention, and treatment of infectious diseases.

KYORIN Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026

KYORIN Pharmaceutical Co., Ltd., 2026 Earnings Call, May 13, 2026

KYORIN Pharmaceutical Co., Ltd. expected to report Fiscal Year 2026 results on May 11, 2026. This event was calculated by S&P Global (Created on January 21, 2026).

KYORIN Pharmaceutical Co., Ltd. announced that it has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO on January 5, 2026, for Lasvic tablets (Lascufloxacin hydrochloride, "Product"). Under the terms of this agreement, Lunatus will be the exclusive partner of the Product in Saudi Arabia, the UAE, Kuwait, Bahrain, Qatar, Oman, Iraq, Lebanon, and Jordan, and KYORIN will register as the Marketing Authorization Holder (MAH) in each country and supply the Product to Lunatus. The Product is an oral fluoroquinolone antibacterial agent developed by KYORIN for respiratory and otorhinolaryngology (ear, nose, and throat: ENT) infections. It is designed to concentrate effectively in lung and ENT tissues while maintaining low systemic exposure, providing potent antibacterial activity at the site of infection. In medium-term business plan, "Vision 110 - Stage 1", KYORIN is proactively pursuing out-licensing activities to maximize the value of KYORIN's proprietary products. Through this partnership with Lunatus, KYORIN aims to make the Product widely available across the Middle East and continue mission of contributing to people's health. The impact on business performance for the fiscal year ending March 2026 is to be negligible.

KYORIN Pharmaceutical Co., Ltd. announced dividend for the second quarter end of year ending March 31, 2026. For the period, the company announced dividend of JPY 20.00 per share compared to JPY 20.00 per share paid a year ago. Scheduled date for starting dividend payment: December 2, 2025.

KYORIN Pharmaceutical Co., Ltd., ¥ 37.0, Cash Dividend, Mar-30-2026